document.pdf
Hamlet BioPharma – the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, has secured continued production of Alpha1-peptide with the Swiss public company Polypeptide Group. The new production, at a larger scale, will be essential for the clinical trial program in bladder cancer, currently advancing towards Phase III.
Hamlet BioPharma announces an important milestone by advancing pharmaceutical manufacturing of the Alpha1 peptide with the Polypeptide Group, a leading CDMO company in peptide synthesis. Through a cooperative effort with the Polypeptide Group’s facilities in Strasbourg and Malmö over the years, Hamlet BioPharma has developed large-scale synthesis methods with Good Manufacturing Practice (GMP) quality. The recent agreement will secure supply of the Alpha1 peptide for use in the formulation of Hamlet BioPharmas lead drug candidate Alpha1H.
The Alpha1H complex, which is produced from the synthetic alpha1 peptide, has shown excellent clinical efficacy and stability.
“Securing Alpha1 peptide production on a large scale is essential at this stage to meet the anticipated demand for Alpha1H as our clinical program for bladder cancer is advancing towards Phase III.”, says Martin Erixon, CEO of Hamlet BioPharma.
For more information, please contact
Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49
catharina.svanborg@hamletpharma.com
Martin Erixon, CEO, Hamlet BioPharma AB, +46 733 00 43 77
martin.erixon@hamletpharma.com